Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel targeted agents plus R-ICE for relapsed or refractory diffuse large B-cell lymphoma
ChiCTR2400082468Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, ifosfamide, carboplatin and etoposide in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete response rate after 3 cycles of chemotherapy. Started Mar 2024; status: recruiting.
02
Drugs
rituximabifosfamidecarboplatinetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400082468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082468.